U.S. markets closed
  • S&P Futures

    4,383.50
    -28.25 (-0.64%)
     
  • Dow Futures

    34,900.00
    -74.00 (-0.21%)
     
  • Nasdaq Futures

    14,865.75
    -172.00 (-1.14%)
     
  • Russell 2000 Futures

    2,228.70
    -8.80 (-0.39%)
     
  • Crude Oil

    73.24
    -0.38 (-0.52%)
     
  • Gold

    1,833.00
    -2.80 (-0.15%)
     
  • Silver

    25.62
    -0.16 (-0.61%)
     
  • EUR/USD

    1.1886
    -0.0010 (-0.08%)
     
  • 10-Yr Bond

    1.2690
    +0.0080 (+0.63%)
     
  • Vix

    17.70
    -0.61 (-3.33%)
     
  • GBP/USD

    1.3956
    -0.0002 (-0.02%)
     
  • USD/JPY

    109.5100
    +0.0490 (+0.04%)
     
  • BTC-USD

    40,128.78
    +207.78 (+0.52%)
     
  • CMC Crypto 200

    954.10
    +23.74 (+2.55%)
     
  • FTSE 100

    7,078.42
    +61.79 (+0.88%)
     
  • Nikkei 225

    27,379.16
    -403.26 (-1.45%)
     

Seelos Therapeutics to Participate in the B. Riley Securities' Neuroscience Conference

·1 min read

NEW YORK, April 15, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the B. Riley Securities' Neuroscience Conference, April 28-29, 2021.

(PRNewsfoto/Seelos Therapeutics, Inc.)
(PRNewsfoto/Seelos Therapeutics, Inc.)

Raj Mehra, Ph.D., Chairman and CEO, will present on Wednesday, April 28th at 11:00am ET.

The B. Riley Securities' Neuroscience Conference will cover key topics across neurodegeneration, neuropsychiatry, and mental health disease areas, with both public and private healthcare companies. For more information about the conference: https://brileyfin.com/events

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Contact Information:

Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference-301269110.html

SOURCE Seelos Therapeutics, Inc.